Document is current
Any future updates will be listed below
-
Authors
Li, Na
Zheng, Hong-Yi
Li, Wei
He, Xiao-Yan
Zhang, Mi
Li, Xia
Tian, Ren-Rong
Dong, Xing-Qi
Shen, Zhi-Qiang
Zheng, Yong-Tang
-
Funding
Funding for this research was provided by:
the Strategic Priority Research Program of the CAS (XDB0490000)
Yunnan Key R & D Program (202403AC100011)
Key Laboratory of Bioactive Peptides of Yunnan Province (HXDT-2022-3)
the National Key R & D Program of China (2023YFC2306700)
the National Natural Science Foundation of China (32070181, 82350710801)
- License Information
-
More Information
Article History
Received: 24 September 2024
Accepted: 30 December 2024
First Online: 8 January 2025
Declarations
:
: The study was approved by the Ethics Committee of Yunnan Infectious Diseases Hospital (approval number: 202115 and 2022004). For the retrospective study, informed consent from participants was waived because of the use of anonymous data. For blood sample collection, we provided detailed information to patients and obtained written informed consent.
: Not applicable.
: The authors declare no competing interests.
